Abstract
The liver acts as a host to many functions hence raising the possibility that any one may be compromised by a single gene defect. Inherited or de novo mutations in these genes may result in relatively mild diseases or be so devastating that death within the first weeks or months of life is inevitable. Some diseases can be managed using conventional medicines whereas others are, as yet, untreatable. In this review we consider the application of early intervention gene therapy in neonatal and fetal preclinical studies. We appraise the tools of this technology, including lentivirus, adenovirus and adeno-associated virus (AAV)-based vectors. We highlight the application of these for a range of diseases including hemophilia, urea cycle disorders such as ornithine transcarbamylase deficiency, organic acidemias, lysosomal storage diseases including mucopolysaccharidoses, glycogen storage diseases and bile metabolism. We conclude by assessing the advantages and disadvantages associated with fetal and neonatal liver gene transfer.
Keywords: Fetal gene therapy, in utero gene therapy, neonatal gene therapy, lysosomal storage disease, mucopolysaccharidosis, hemophilia, glycogen storage disease, liver, viral vector, Coagulation factor X
Current Pharmaceutical Design
Title: Perinatal Gene Transfer to the Liver
Volume: 17 Issue: 24
Author(s): Tristan R. McKay, Ahad A. Rahim, Suzanne M.K. Buckley, Natalie J. Ward, Jerry K.Y.Chan, Steven J. Howe and Simon N. Waddington
Affiliation:
Keywords: Fetal gene therapy, in utero gene therapy, neonatal gene therapy, lysosomal storage disease, mucopolysaccharidosis, hemophilia, glycogen storage disease, liver, viral vector, Coagulation factor X
Abstract: The liver acts as a host to many functions hence raising the possibility that any one may be compromised by a single gene defect. Inherited or de novo mutations in these genes may result in relatively mild diseases or be so devastating that death within the first weeks or months of life is inevitable. Some diseases can be managed using conventional medicines whereas others are, as yet, untreatable. In this review we consider the application of early intervention gene therapy in neonatal and fetal preclinical studies. We appraise the tools of this technology, including lentivirus, adenovirus and adeno-associated virus (AAV)-based vectors. We highlight the application of these for a range of diseases including hemophilia, urea cycle disorders such as ornithine transcarbamylase deficiency, organic acidemias, lysosomal storage diseases including mucopolysaccharidoses, glycogen storage diseases and bile metabolism. We conclude by assessing the advantages and disadvantages associated with fetal and neonatal liver gene transfer.
Export Options
About this article
Cite this article as:
R. McKay Tristan, A. Rahim Ahad, M.K. Buckley Suzanne, J. Ward Natalie, K.Y.Chan Jerry, J. Howe Steven and N. Waddington Simon, Perinatal Gene Transfer to the Liver, Current Pharmaceutical Design 2011; 17 (24) . https://dx.doi.org/10.2174/138161211797247541
DOI https://dx.doi.org/10.2174/138161211797247541 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
Current Cancer Drug Targets Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry Natural and Synthetic Retinoids: Structural Bases and Biological Effects of Potential Clinical Relevance for the Prevention and Treatment of Infection-Driven Tumors
Anti-Infective Agents in Medicinal Chemistry Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Establishment of a Primary Screening Assay for the DHX9 Helicase
Combinatorial Chemistry & High Throughput Screening DNA Methylation Markers in Lung Cancer
Current Genomics Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) The Signaling Function of the IL-13Rα2 Receptor in the Development of Gastrointestinal Fibrosis and Cancer Surveillance
Current Molecular Medicine The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Standards and Novel Therapeutic Options in the Treatment of Patients with Soft Tissue Sarcoma
Reviews on Recent Clinical Trials Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design A Review on Hemisynthesis, Biosynthesis, Biological Activities, Mode of Action, and Structure-Activity Relationship of Podophyllotoxins: 2003- 2007
Current Medicinal Chemistry Solvent Modulation of Column Chromatography
Protein & Peptide Letters A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Current Signal Transduction Therapy The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets